This was the third seminar jointly organized by The University of Hong Kong, The University of Macau as well as the Pharmaceutical Society of Macao, supported and sponsored by the HKAPI. Every year the seminar explores a certain theme surrounding the status quo and future development of the pharmaceutical systems of both cities. For this year, the scope has been expanded to cover also Mainland China, as the Guangdong-Hong Kong-Macao Greater Bay Area remains one of the hottest topics for both the pharmaceutical industry and the academia alike.

More than 80 people joined the event this year at the Wu Yee Sun Library of the University of Macau. Same as the previous two years, the whole-day seminar was split into morning and afternoon sessions discussing separate topics. Other than exploring the roles of Macao, Hong Kong and Mainland China in the pharmaceutical regulatory framework of the Greater Bay Area, this year the seminar also looked at the latest trend of real world evidence and regulatory science in the three economies.

The following renowned experts were invited as speakers this year (in sequence of appearance):
1. Prof. SHI Lu-wen, Director, Department of Pharmacy Administration & Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University
北京大學藥學院藥事管理與臨床藥學系主任史錄文教授,
2. Mr. Raphael Yeung, Senior Pharmacist (Advanced Therapy Product), Drug Office, Department of Health, HKSAR Government
香港特別行政區政府衛生署藥物辦公室高級藥劑師(牌照及監察-製藥商)楊義輝先生
3. Prof. HU Yuan-jia, Associate Professor, Institute of Chinese Medical Sciences, University of Macau
澳門大學中華醫藥研究院副教授胡元佳教授
4. Prof. Ian Wong, Head, Department of Pharmacology & Pharmacy, University of Hong Kong
香港大學李嘉誠醫學院藥理及藥劑學系系主任黃志基教授
5. Dr. Carolina Ung, Lecturer, Institute of Chinese Medical Sciences, University of Macau
澳門大學中華醫藥研究院講師吳靄琳博士
6. Dr. XU Li-ping, Council Member, China Society for Drug Regulation
中國藥品監督管理研究會理事會員許立平博士
7. Dr. ZHU Jin, Principal Toxicologist, Therapeutic Goods Administration, Australia
澳洲醫療用品管理局首席毒物學家朱金博士